Drugs / EEC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06305104 | Jul 2023 → May 2024 | tuberculosis | Chengdu CoenBiotech Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EEC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06305104 ↗ |
| Modality | Protein / enzyme biologic | “recombinant mycobacterium tuberculosis fusion protein ( EEC)” NCT06305104 ↗ |